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hospitalized for ≥ 2 days (hospitalized patients; HPs), or using emergency room (ER) 
or observation for 1 day (emergency room patients; ERPs). Reimbursements were 
based on claims and inflated to 2010 USD; costs were derived from 2010 Premier 
data. Net reimbursement was analyzed by MS-DRG and length of stay (LOS). The 
risk of all-cause hospitalization and factors correlated with LOS were determined 
using regression modeling. Results: Across all study years, the median age was 
71 for HPs, 65 for ERPs. Median Charlson Comorbidity Index (CCI) was 4 for HPs and 
2 for ERPs. HPs had more cellulitis on the leg or surgical infection; ERPs had more 
cellulitis on the face, trunk, or arm. Median HP LOS was 4 days; 33% of patients had 
LOS > 6 days. Age, race, and history of bacterial infection were correlated with LOS. 
Median all-cause, ABSSSI-related and index event costs during the index quarter 
for patients with a principle ABSSSI diagnosis were $9,930, $6,123 and $5,604 for 
HPs and $1,127, $108 and $100 for ERPs respectively. ConClusions: HPs were older 
and sicker than ERPs, with more cellulitis on the leg and post-operative infections. 
Further research and analysis may help determine whether treating some hospital-
ized patients with less comorbidity in the ambulatory setting might result in lower 
costs per patient after controlling for these factors.
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objeCtives: The aims of this study were to determine the clinical consequences 
and non-pharmacological costs of the usage of oral anticoagulation (OAC) therapy 
for the treatment of atrial fibrillation (AF) at EsSalud in Peru. Methods: A markov 
model was adapted to evaluate the clinical and economic impact of OAC on a cohort 
of 1,000 patients among the AF vitamin K antagonists (VKA) suitable population 
at EsSalud in Peru. Comparators for the analysis are: apixaban 5mg BID, warfarin 
5mg and aspirin 150mg. A lifetime horizon and EsSalud´s perspective were used. 
A discount rate of 3.5% was applied to both costs and outcomes. Efficacy data was 
taken from the clinical trials for apixaban, ARISTOTLE and AVERROES, which directly 
compared apixaban with warfarin and apixaban with aspirin, respectively. Resource 
utilization for each event was collected from a clinical chart review at a specialized 
care center of EsSalud. All costs were taken from EsSalud´s 2013 tarrifs and are 
expressed in 2013 US dollars. Results were validated by an expert panel of clinicians 
from EsSalud. Results: The number of events associated with each anticoagu-
lant therapy (apixaban, warfarin and aspirin respectively) were: stroke (ischemic 
and hemorrhagic) and systemic embolism 309, 352, 352, major bleedings 116, 149, 
102; and event related deaths 401, 447, 445, respectively. Apixaban was associated 
with a reduction of the non-pharmacological costs when compared with warfarin 
and aspirin in the range of $245 – $1,282. ConClusions: Over a lifetime horizon 
apixaban demonstrates a reduction in the number of AF complication events and 
reduction in non-pharmacological costs at EsSalud.
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objeCtives: To asses the costs and financial consequences of epidemiological 
changes for chronic diseases (HYPERTENSION AND DIABETES) in a middle-income 
country. Methods: An evaluative approach based on a longitudinal design was 
used. Direct costs were determined for the functions of production, standards of 
quality and the estimation of inputs costs. Indirect costs were determined by using a 
human capital model for Latin America which uses indicators of premature mortal-
ity and disability (temporary or permanent). Probabilistic models were developed 
to estimate epidemiological changes during 2010-2012 by using the Box-Jenkins 
technique. Finally, the economic burden was obtained for disease by applying an 
econometric adjustment factor. Results: Taking hypertension results, compar-
ing the economic impact in 2010 versus 2012 (p< 0.05), there is a 24% increase in 
financial requirements. The total amount for hypertension in 2011 (US dollars) was 
$ 5733,350,291. It include $ 2718,280,941 in direct costs and $ 3015,069,350. Costs for 
hypertension are permanently increasing in regards to economic burden, showing 
an increase of 33%. This average has differences for insured and uninsured popula-
tions. ConClusions: Health care systems and society in middle income countries 
will face important challenges on health financing, universal effective coverage and 
financial protection for the uninsured, if the risk factors and the health care model 
remain as currently are. The major economic impact of chronic diseases will be in 
users out of pocket expenditures because of indirect costs. We suggest an important 
reorganization of the planning process, the health care model and the allocation of 
resources mechanisms, in order to strengthen health care and access to hospital 
and outpatient services for patients suffering a chronic disease.
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objeCtives: Visual loss is significantly associated with increased risk of mortality 
and decreased quality of life. In Prince Edward Island (PEI), Canada, eye examination 
and cost of eyeglasses are not covered by provincial health insurance. This study 
aimed to assess the cost-effectiveness of insured eye examination compared to non-
insured eye examination for PEI residents. Methods: A cost-effectiveness analysis 
was conducted from a perspective of Canada’s health care system. A target popula-
tion was a PEI resident aged 42 years or older. Risk of vision loss and utility data were 
of care for different categories of patients including cost of health care provider time 
per visit, lab tests, ARV drugs and non ARV drugs. Results: The cost of treatment 
for an HIV positive patient with a CD4 count > 350 cells/ uL who has not started 
ART was $51/year. The cost of treating a patient on first line therapy in the first 
year of ART was $218, and thereafter $284/yr. The cost of a patient on second line 
ART was $1393/year. The cost of treatment of pregnant and patients co-infected 
with M. tuberculosis was $229/year and $413/year respectively. The costs are driven 
predominantly by ARV costs. ConClusions: This analysis shows the actual costs 
of HIV care at a larger urban HIV clinic in SSA. The increasing number of patients on 
second line ARVs is likely to dramatically increase the financial burden on health 
services in SSA in the future.
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objeCtives: Approaches for predicting cost accumulation for heterogeneous 
samples are limited. We employ the Grouping Algorithm for Cancer Cost Data 
(GACCD) to investigate cost accumulation over time and identify ‘high cost’ 
patients. Methods: Two-fold cross validation was used to evaluate survival and 
cost accumulation using linked prostate cancer (PCa) registry and Medicare claims 
data from 1999-2009. Patients were grouped according to a refined similarity metric 
using five patient characteristics (cancer stage, age, Charlson Comorbidity Index 
(CCI), performance proxy indicator, race). Cost accumulation was evaluated in the 
test dataset for the GACCD groups identified in the training data. Curves using the 
test data plotted inverse probability weighted cumulative average total monthly 
costs (CATMC) for the post-diagnosis period and the proportion of people who were 
deemed to be ‘high cost’. Results: Application of the inclusion criteria resulted in 
110,824 patients. Median (mean) follow up was 48 (51) months and the mortality rate 
was 27.3%. The five GACCD groups had distinguishing characteristics e.g., group2 
patients were typically older, with CCI above 2 and/or diagnosed with either later 
stage or unstaged PCa; group3 patients were typically younger, with CCI= 0 and diag-
nosed with early stage PCa. Cost accumulation within the first three years varied 
across the groups, with the lowest (highest) rate in group3 (group2) in the training 
dataset. Using the test data: at a threshold of $10,000 in CATMC, the proportion of 
patients that was high cost within three years following diagnosis ranged from 
82% in group3 to 90% in group2; proportions ranged from 45% in group3 to over 
60% in group2 at a threshold of $25,000; proportions ranged from 15% in group3 to 
over 30% in group2 at a threshold of $50,000. ConClusions: A grouping algorithm 
with a refined similarity metric can identify patient subgroups that will accumulate 
higher costs over time.
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objeCtives: (1)Survey to estimate the monthly expenditure of a Type II Diabetes 
patient in Mumbai . (2)To project the fact that even in absence of health insurance 
policies by government for its citizens, patients receive free or cost subsidized treat-
ment in the government hospitals. (3)Explore government initiatives in regulating 
the price of the Diabetes II drugs. Methods: Three sets of structured question-
naires were designed which captured the patient demographics,prescription trends 
of type II Diabetes patients in Mumbai,India.The survey through questionnaires tar-
geted three government secondary hospitals,two government tertiary hospitals,35 
General Practioners,50 Drug stores. Results: (1) 46%of the patients detected with 
type II Diabetes lie in the age group of 50-60 years. (2)Amongst them the population 
of males affected is little more than females ie.51% males vs 46% females. (3)The 
trend of drugs as prescribed by the General Practioners is same as that of drug pre-
scriptions received by drug stores.The Metformin containing generic brands which 
fall under The Drug Price Control Order(DPCO) 2013 (cap price removed)is majorly 
prescribed followed by glypizides , acarbose and pioglitazone containing generic 
brands. ConClusions: : (1)The monthly expenditure of a Type II Diabetes patient in 
Mumbai is Rs.300 (USD 4.8)when the patient is treated by GP and purchases the drug 
from the drug stores. (2)The patients are either treated free or in subsidized rates 
in government hospitals.ie.in 2.4USD per month. (3)The metformin category drugs 
coming under DPCO 2013 are the majorly prescribed drugs. Thus it is very easy and 
convenient for type II Diabetes patients in Mumbai to suffice their medical needs in 
the most reasonable and affordable price and also get free treatment from tertiary 
government hospitals.Although a federal/government health insurance policy does 
not exist in India the government through its subsidies or free treatments rightly 
makes this therapy accessible to the common man of the city.
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objeCtives: Recent clinical trials of antibiotics targeted to ABSSSI have included 
large proportions of patients treated in the ambulatory setting. An objective of 
this study of real-world patient transaction data was to analyze differences 
between Medicare patients treated in the inpatient versus the ambulatory set-
ting. Methods: Analysis used Medicare 5% Limited Data Set (LDS) files contain-
ing claims for 27,607 patients age ≥ 18 with a principal diagnosis of ABSSSI between 
Q4, 2007 – Q3, 2010 from a 5% sample of Medicare beneficiaries, including patients 
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objeCtives: HIV/AIDS prevalence in Colombia is 0,8%. Currently for the country 
is important to assess the effectiveness and impact of its practices on the health 
of its population. A health maintenance organization (HMO) with national cover-
age aims to contribute by assessing the health outcomes of its care program for 
HIV/AIDS patients, a high cost disease with great impact on HRQOL. To evaluate the 
cost-effectiveness of the care program for HIV/AIDS patients insured by a HMO in 
Colombia, comparing its results in three health care providers (HCP). Methods: A 
Markov model in MS Excel® was built to represent the natural history of HIV/AIDS 
based on the staging of the disease given by WHO according to the CD4 lymphocytes 
level. Direct costs were included, according to the information available on HMO´s 
databases. The outcome measure were QALY’s taken from the literature. Transition 
probabilities were calculated from tracking a cohort of 884 HIV/AIDS patients over 
18 years old, from three health providers (HCP A, B and C) in 7 cities across the coun-
try, during 2011 and 2012. Time horizon was lifetime. Perspective was third payer. 
Deterministic and probabilistic sensitivity analysis were performed. Results: HCP 
C was dominated. HCP A versus HCP B ICER was USD$2.497 per life year gained and 
USD$3.674 per QALY. Annual average cost per patient by stage was: stage 1 USD$2.347, 
USD$2.281 stage 2, stage 3 USD$3.022, USD$4.103 stage 4 and USD$6.994 for stage 
5. ConClusions: Given a willingness to pay 1 GDP per capita for the country, the HCP 
B is a very cost-effective option. The average annual cost of patients in stage 5 is three 
times stage 1. PRiMARy Funding souRCe: health maintenance organization (HMO).
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objeCtives: Breast magnetic resonance imaging (MRI) is a sensitive method of 
breast screening and is increasingly being used for detection of breast cancer among 
high risk young women. However, the specificity of breast MRI is relatively low and 
costs are quite high. The purpose of this study was to determine if breast MRI is 
a cost-effective approach for the detection of breast cancer among young women 
at high risk. Methods: A Markov model was built up to compare annual breast 
cancer screening with either breast MRI or mammography among young women 
who have more than 15% lifetime risk of breast cancer. Data from published studies 
provided probabilities for the model inputs. All costs and benefits were discounted 
at 5% per year. The analysis was performed from societal perspective with results 
reported in 2013 U.S. dollars. One-way and net benefits sensitivity analyses addressed 
uncertainty in model parameters. Results: Breast MRI provided 19.38 discounted 
quality-adjusted life-years (QALYs) at a discounted cost of $37,765 while mam-
mography provided 19.14 QALYs at a cost of $23,226 over 30 years of screening. The 
incremental cost-effectiveness ratio of breast MRI compared to mammography was 
$59547/QALY. In one-way sensitivity analysis and net benefits sensitivity analysis, the 
cost-effectiveness or net benefits of MRI screening depends critically on the accuracy 
of both MRI and mammography. ConClusions: Annual MRI screening of women 
who have more than 15% lifetime risk of breast cancer was found to be potentially 
cost-effective, with an ICER of $59547/QALY when compared to annual mammography 
alone. The benefits of early detection of breast cancer with MRI in this population may 
outweigh the added cost of screening and the higher risk of false positives. However, 
the cost-effectiveness of MRI screening is highly dependent on the accuracy of MRI 
and Mammography. There remains some statistical uncertainty around this result.
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objeCtives: Untreated syphilis in pregnancy is associated with adverse clinical 
outcomes to the infant. In low and middle income countries in Asia, roughly one 
out of three women is not tested for syphilis during pregnancy. The objective of 
this analysis was to evaluate the cost-effectiveness, budget impact, and potential 
reduction in adverse pregnancy outcomes of antenatal syphilis screening using 
the recently introduced point of care immunochromatographic strip (ICS) test for 
11 select countries in Asia. Methods: A previously published cost-effectiveness 
model was adapted to reflect the perspectives of the respective national health 
care systems. Clinical outcomes of infants born to syphilis-infected mothers on 
the endpoints of stillbirth, neonatal death and congenital syphilis were obtained 
from published sources. Treatment was assumed to consist of three injections of 
benzathine penicillin. Country-specific inputs included the antenatal prevalence 
of syphilis; annual number of live births; proportion of women with at least one 
antenatal care visit; per capita gross national income and estimated hourly nurse 
wages. Results: In all 11 Asian countries, syphilis screening is highly cost-effec-
tive with an weighted average cost/DALY averted of US$82 (range: US$22-US$518). 
Universal screening may reduce the annual number of stillbirths by up to 10,000, 
neonatal deaths by up to 4,000, the annual incidence of congenital syphilis by up to 
5,000 and avert up to 450,000 DALYs at an incremental annual direct medical cost of 
US$23.0 million. Due to its low screening rate of 0.1%, Indonesia accounts for almost 
50% of DALYs that could be averted. In contrast, Laos, Malaysia, and Thailand are 
close to universal screening and leave little room for improvement. ConClusions: 
The use of ICS tests for antenatal syphilis screening is highly cost-effective in low 
and middle income countries in Asia. Antenatal programs should either expand or 
maintain full access to syphilis screening using the ICS test.
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obtained from published literature. Resource utilization and costs associated with 
managing vision loss and eye examination were obtained from Health PEI, Ontario 
Ministry of Health and Long-term Care, and published literature. A decision analytic 
model was used to estimate an incremental cost-effectiveness ratio (ICER). Costs 
were expressed in 2012 Canadian dollars. A series of sensitivity analyses, including 
one-way and two-way sensitivity analyses, was performed to assess the possible 
uncertainty and robustness of our findings. Results: Compared with non-insured 
eye examination, insured eye examination for PEI residents led to an annual gain of 
0.01 quality adjusted life year (QALY) and an incremental cost of $5.52 per person, 
yielding an ICER of $2,785 per QALY. Sensitivity analyses showed that cost-effective 
estimates were highly sensitive to the incidence of vision loss, rate of eye examination 
by optometrists, and utility of vision loss. Specifically, higher incidence of vision loss 
and greater rate of eye examination by optometrists offered lower cost-effectiveness 
ratios. ConClusions: Insured eye examination for PEI residents was a highly cost-
effective option compared to non-insured eye examination. This intervention was 
even more cost-effective if greater proportion of PEI residents received the eye exami-
nation by optometrists and if the incidence of vision loss in PEI increased.
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objeCtives: Clinic evidence shows that nephroprotection programs in patients 
with chronic kidney disease improve patient’s health, life expectancy and reduce 
hospitalizations and early deaths. In Mexico, there are few nephroprotection 
programs. The purpose of this study was to analyze a nephroprotection program 
in patients of the Mexican Institute of Social Security with chronic kidney dis-
ease aimed to improve life expectancy and to reduce hospitalizations and early 
deaths. Methods: The study design was a cost-effectiveness analysis from the 
governmental perspective. All the costs were obtained from the Diagnosis-related 
groups that Mexican Institute of Social Security publishes. Costs were expressed 
in 2013 constant USD. A Markov model with forty eight monthly cycles was used. 
We considered five chronic kidney disease stages according to US National Kidney 
Foundation and also death stage. Parameters were obtained from other nephropro-
tection programs and also from the Mexican Institute of Social Security statistics. 
Years life gained, hospitalizations and early deaths avoided ICER were estimated 
and discounted at 5% annual rate. Univariate sensitivity analysis for costs was 
performed. Also we conducted budget impact analysis. Results: The nephro-
protection program was cost-saver for cost per year life gained (ICER= $-1,477) 
and for hospitalizations avoided (ICER= $-4,984) and cost-effective for early death 
avoided (ICER= $22,738). The program increases thirteen months life expectancy, 
reduces 50% hospitalizations and avoids 21,118 deaths in a four-year horizon. The 
hospitalizations avoided also allow increasing hospital supply in 67%. The budget 
impact analysis showed that the program could achieve savings of 42% for the 
Institute. ConClusions: The nephroprotection program could improve patient’s 
health and reduce disease progression, therefore, it could be considered for imple-
mentation in the Mexican Institute of Social Security.
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objeCtives: The follow-up rate among children with vision problems in our out-
reach programs has been poor (< 5%). We therefore developed the Children’s Eye 
Care Adherence Program (CECAP) for Philadelphia school children, a social worker 
(SW) intervention to address barriers to care among children with significant vision 
problems. The objective of this study was to measure CECAP’s effectiveness and cost. 
We also sought to identify barriers to care through a conceptual framework and 
geomapping software. Methods: CECAP included SW review of records to identify 
children needing follow-up. SW phoned families to identify and resolve barriers to 
eye care and scheduled appointment. Effectiveness was defined as the percent com-
pleting ≥ 1 follow-up visit within the physician-recommended time frame. Cost was 
measured using SW time logs (converted to costs using SW wage rates + benefits) 
and additional materials (forms, postage, phone charges). Barriers were organized 
into a conceptual framework depicting 3 main themes (predisposing factors, system 
factors, and ability to pay) and mapping software to visually illustrate follow-up 
rate. Results: Of 1200 patients, 120 required follow-up ophthalmic care in 2012-
13. 71 patients were reached and completed a follow-up (59.2%); 49 patients were 
reached but did not follow-up (40.8%). SW time was ~3hrs/patient for those who 
followed up and ~2hrs/patient for those that did not. Based on the CECAP program 
total cost ($14,249) and the reimbursement payment ($6,265.66), the net cost of 
the CECAP program was $7,983.59. Predisposing factors (lack of awareness, level of 
perceived importance, conflict of commitment, lack of means of communication) 
was the primary barrier theme for patients that did not follow-up. ConClusions: 
CECAP significantly improved adherence to eye care but comes at an additional 
cost. Future efforts should focus on reducing operational efficiencies (e.g., capping 
outreach attempts) and targeting CECAP based on predictors of follow-up.
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